程序性细胞死亡配体1的显像:在免疫健全的小鼠黑色素瘤模型中,蛋白浓度对抗PD-L1 SPECT显像剂分布的影响
本研究在侵袭性黑色素瘤小鼠模型中评估蛋白浓度对111In-DTPA-抗PD-L1分布的影响。结果显示,111In-DTPA-抗PD-L1(解离常数0.6±0.1 nM)在蛋白浓度等于或超过1 mg/kg(24小时)和3 mg/kg(72小时)时,B16F10肿瘤摄取增加。结论认为该显像剂能够识别过表达PD-L1的肿瘤,并监测富PD-L1器官对抗PD-L1抗体分布的影响。
要点
- 111In-DTPA-抗PD-L1的解离常数为0.6±0.1 nM。
- 蛋白浓度等于或超过1 mg/kg时24小时肿瘤摄取增加,等于或超过3 mg/kg时72小时肿瘤摄取增加。
- 随冷抗体量增加,两个时间点循环中示踪剂残留量均增加。
核心结论
- 111In-DTPA-抗PD-L1能够识别过表达PD-L1的肿瘤,并监测富PD-L1器官对抗PD-L1抗体分布的影响。
研究设计与样本
- 在侵袭性黑色素瘤小鼠模型中评估蛋白浓度对111In-DTPA-抗PD-L1分布的影响。
主要发现
- 111In-DTPA-抗PD-L1的解离常数为0.6±0.1 nM。
- 在蛋白浓度等于或超过1 mg/kg时24小时B16F10肿瘤摄取增加,在蛋白浓度等于或超过3 mg/kg时72小时B16F10肿瘤摄取增加。
- 24小时时,富PD-L1的脾和肺摄取随蛋白浓度增加而降低。
- 72小时时,蛋白浓度等于或超过3 mg/kg时胸腺摄取显著增加。
- 两个时间点均显示,随冷抗体量增加,循环中示踪剂残留量增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Programmed cell death ligand 1 (PD-L1) is part of an immune checkpoint system that is essential for preventing autoimmunity and cancer. Recent approaches in immunotherapy that target immune checkpoints have shown great promise in a variety of cancers, including metastatic melanoma. The use of targeted molecular imaging would help identify patients who will best respond to anti-PD-L1 treatment while potentially providing key information to limit immune-related adverse effects. Recently, we developed an antibody-based PD-L1-targeted SPECT agent-111In-diethylenetriaminepentaacetic acid (DTPA)-anti-PD-L1-to identify PD-L1-positive tumors in vivo. To best use such PD-L1-targeted imaging agents, it is important, as a first step, to understand how the signal is affected by different parameters. Methods: We evaluated the impact of protein concentration on the distribution of 111In-DTPA-anti-PD-L1 in a murine model of aggressive melanoma. Results:111In-DTPA-anti-PD-L1 (dissociation constant, 0.6 ± 0.1 nM) demonstrated increased uptake in B16F10 tumors at protein concentrations equaling or exceeding 1 mg/kg at 24 h and 3 mg/kg at 72 h. At 24 h, the PD-L1-rich spleen and lungs demonstrated decreasing uptake with increasing protein concentration. At 72 h, uptake in the thymus was significantly increased at protein concentrations of 3 mg/kg or greater. Both time points demonstrated increased tracer amounts remaining in circulation as the amount of cold antibody was increased. Conclusion: These studies demonstrate that 111In-DTPA-anti-PD-L1 is capable of identifying tumors that overexpresses PD-L1 and monitoring the impact of PD-L1-rich organs on the distribution of anti-PD-L1 antibodies.
引用
- Nedrow JR, Josefsson A, Park S, et al. Imaging of Programmed Cell Death Ligand 1: Impact of Protein Concentration on Distribution of Anti-PD-L1 SPECT Agents in an Immunocompetent Murine Model of Melanoma. J Nucl Med. 2017. PMID: 28522738. doi:10.2967/jnumed.117.193268
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。